Singulair, an oral asthma drug, can reduce symptoms in youngsters who have intermittent asthma flare-ups linked to infection, a new study reports.After taking Singulair (montelukast) for 12 months, the children in the study had a 32 percent reduced rate of asthma exacerbations, while their use of inhaled corticosteroid medications was reduced by 40 percent."For the first time ever, an option for treatment of viral-induced intermittent asthma has proven effective,” said study author Dr. Hans Bisgaard, a professor of pediatrics at Copenhagen University Hospital in Denmark.Results of the study appear in the Feb. 15 issue of the American Journal of Respiratory and Critical Care Medicine.
